Symbols / AXSM $186.42 +1.89% Axsome Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
AXSM Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.

Fundamentals
Scroll to Statements
Market Cap 9.54B Enterprise Value 9.25B Income -183.17M Sales 638.50M Book/sh 1.74 Cash/sh 6.31
Dividend Yield — Payout 0.00% Employees 925 IPO — P/E — Forward P/E 30.45
PEG — P/S 14.94 P/B 107.45 P/C — EV/EBITDA -57.78 EV/Sales 14.49
Quick Ratio 1.45 Current Ratio 1.55 Debt/Eq 247.03 LT Debt/Eq — EPS (ttm) -3.68 EPS next Y 6.12
EPS Growth — Revenue Growth 65.00% Earnings 2026-05-04 ROA -16.81% ROE -252.12% ROIC —
Gross Margin 92.56% Oper. Margin -18.38% Profit Margin -28.69% Shs Outstand 51.15M Shs Float 43.24M Short Float 6.56%
Short Ratio 4.92 Short Interest — 52W High 191.50 52W Low 96.09 Beta 0.47 Avg Volume 585.88K
Volume 614.02K Target Price $223.99 Recom Strong_buy Prev Close $182.97 Price $186.42 Change 1.89%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$223.99
Mean price target
2. Current target
$186.42
Latest analyst target
3. DCF / Fair value
$-10.35
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$186.42
Low
$198.82
High
$260.00
Mean
$223.99

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-10 main UBS Buy → Buy $259
2026-03-25 main Guggenheim Buy → Buy $245
2026-02-24 main UBS Buy → Buy $251
2026-02-24 main Guggenheim Buy → Buy $220
2026-02-24 main RBC Capital Outperform → Outperform $222
2026-02-24 main Wells Fargo Overweight → Overweight $202
2026-02-24 init Wolfe Research — → Outperform $230
2026-02-23 reit Needham Buy → Buy $225
2026-02-03 main Jefferies Buy → Buy $245
2026-01-28 main Leerink Partners Outperform → Outperform $205
2026-01-21 main RBC Capital Outperform → Outperform $219
2026-01-20 main HC Wainwright & Co. Buy → Buy $260
2026-01-16 main Piper Sandler Overweight → Overweight $223
2026-01-13 main Wells Fargo Overweight → Overweight $193
2026-01-08 down Morgan Stanley Overweight → Equal-Weight $204
2026-01-06 main UBS Buy → Buy $248
2026-01-05 main HC Wainwright & Co. Buy → Buy $200
2025-12-31 main Needham Buy → Buy $169
2025-11-06 main Mizuho Outperform → Outperform $202
2025-11-04 main Morgan Stanley Overweight → Overweight $196
News
RSS: Latest AXSM news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-26 COLEMAN MARK H Director — 25,000 $161.11 $4,027,750
2026-02-26 JACOBSON MARK L Chief Operating Officer — 35,378 $161.88 $5,726,991
2026-02-26 JACOBSON MARK L Chief Operating Officer — 35,378 $2.85 $100,827
2026-02-23 COLEMAN MARK H Director — 6,250 $4.95 $30,938
2026-02-20 COLEMAN MARK H Director — 12,485 $4.95 $61,801
2026-02-10 COLEMAN MARK H Director — 5,193 $8.02 $41,648
2026-02-02 TABUTEAU HERRIOT Chief Executive Officer — 32,410 $185.60 $6,015,296
2026-02-02 TABUTEAU HERRIOT Chief Executive Officer — 32,410 $8.02 $259,928
2026-01-22 PIZZIE NICK Chief Financial Officer — 12,000 $187.92 $2,255,040
2026-01-22 PIZZIE NICK Chief Financial Officer — 12,000 $3.50 $42,000
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
638.50
+65.55%
385.69
+42.53%
270.60
+440.80%
50.04
Operating Revenue
638.50
+65.55%
385.69
+42.53%
270.60
+440.80%
50.04
Cost Of Revenue
47.48
+42.56%
33.30
+27.77%
26.07
+401.44%
5.20
Reconciled Cost Of Revenue
44.79
+41.13%
31.74
+23.94%
25.61
+418.87%
4.93
Gross Profit
591.02
+67.72%
352.39
+44.11%
244.53
+445.36%
44.84
Operating Expense
760.25
+25.70%
604.83
+41.50%
427.44
+93.12%
221.34
Research And Development
183.28
-2.03%
187.08
+91.00%
97.94
+69.02%
57.95
Selling General And Administration
570.60
+38.71%
411.36
+27.31%
323.12
+102.90%
159.25
General And Administrative Expense
—
—
—
—
Other Gand A
—
—
—
—
Total Expenses
807.73
+26.58%
638.13
+40.71%
453.51
+100.19%
226.54
Operating Income
-169.24
+32.96%
-252.44
-38.01%
-182.91
-3.63%
-176.50
Total Operating Income As Reported
-166.76
+40.56%
-280.56
-21.02%
-231.82
-28.94%
-179.80
EBITDA
-168.08
+38.34%
-272.60
-21.16%
-224.99
-28.28%
-175.40
Normalized EBITDA
-160.17
+34.49%
-244.48
-38.85%
-176.07
-2.31%
-172.10
Reconciled Depreciation
9.06
+13.90%
7.96
+16.45%
6.83
+55.25%
4.40
EBIT
-177.15
+36.86%
-280.56
-21.02%
-231.82
-28.94%
-179.80
Total Unusual Items
-7.91
+71.87%
-28.12
+42.51%
-48.92
-1383.26%
-3.30
Total Unusual Items Excluding Goodwill
-7.91
+71.87%
-28.12
+42.51%
-48.92
-1383.26%
-3.30
Special Income Charges
-7.91
+71.87%
-28.12
+42.51%
-48.92
-1383.26%
-3.30
Other Special Charges
10.38
—
—
—
Restructuring And Mergern Acquisition
-2.47
-108.79%
28.12
-42.51%
48.92
+1383.26%
3.30
Net Income
-183.17
+36.22%
-287.22
-20.05%
-239.24
-27.84%
-187.13
Pretax Income
-183.70
+36.02%
-287.13
-20.50%
-238.28
-27.33%
-187.13
Net Non Operating Interest Income Expense
-6.56
+0.18%
-6.57
-1.80%
-6.45
+12.02%
-7.33
Interest Expense Non Operating
6.56
-0.18%
6.57
+1.80%
6.45
-12.02%
7.33
Net Interest Income
-6.56
+0.18%
-6.57
-1.80%
-6.45
+12.02%
-7.33
Interest Expense
6.56
-0.18%
6.57
+1.80%
6.45
-12.02%
7.33
Other Income Expense
-7.91
+71.87%
-28.12
+42.51%
-48.92
-1383.26%
-3.30
Tax Provision
-0.53
-723.53%
0.09
-91.15%
0.96
0.00
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
0.00
Tax Effect Of Unusual Items
-0.02
0.00
+100.00%
-10.27
0.00
Net Income Including Noncontrolling Interests
-183.17
+36.22%
-287.22
-20.05%
-239.24
-27.84%
-187.13
Net Income From Continuing Operation Net Minority Interest
-183.17
+36.22%
-287.22
-20.05%
-239.24
-27.84%
-187.13
Net Income From Continuing And Discontinued Operation
-183.17
+36.22%
-287.22
-20.05%
-239.24
-27.84%
-187.13
Net Income Continuous Operations
-183.17
+36.22%
-287.22
-20.05%
-239.24
-27.84%
-187.13
Normalized Income
-175.29
+32.35%
-259.09
-29.16%
-200.59
-9.12%
-183.84
Net Income Common Stockholders
-183.17
+36.22%
-287.22
-20.05%
-239.24
-27.84%
-187.13
Diluted EPS
-3.68
+38.56%
-5.99
-13.66%
-5.27
-14.57%
-4.60
Basic EPS
-3.68
+38.56%
-5.99
-13.66%
-5.27
-14.57%
-4.60
Basic Average Shares
49.75
+3.83%
47.91
+5.48%
45.43
+11.73%
40.66
Diluted Average Shares
49.75
+3.83%
47.91
+5.48%
45.43
+11.73%
40.66
Diluted NI Availto Com Stockholders
-183.17
+36.22%
-287.22
-20.05%
-239.24
-27.84%
-187.13
Amortization
6.38
-0.27%
6.39
+0.27%
6.38
+54.02%
4.14
Amortization Of Intangibles Income Statement
6.38
-0.27%
6.39
+0.27%
6.38
+54.02%
4.14
Depreciation Amortization Depletion Income Statement
6.38
-0.27%
6.39
+0.27%
6.38
+54.02%
4.14
Depreciation And Amortization In Income Statement
6.38
-0.27%
6.39
+0.27%
6.38
+54.02%
4.14
Other Taxes
—
—
—
0.00
Line Item Trend 2023-12-31
Total Assets
588.24
Current Assets
504.26
Cash Cash Equivalents And Short Term Investments
386.19
Cash And Cash Equivalents
386.19
Cash Financial
—
Receivables
94.82
Accounts Receivable
94.82
Gross Accounts Receivable
107.32
Allowance For Doubtful Accounts Receivable
-12.50
Inventory
15.13
Prepaid Assets
—
Other Current Assets
8.12
Total Non Current Assets
83.97
Net PPE
7.62
Gross PPE
7.62
Properties
0.00
Buildings And Improvements
6.77
Other Properties
0.85
Goodwill And Other Intangible Assets
65.33
Goodwill
12.04
Other Intangible Assets
53.29
Other Non Current Assets
11.03
Total Liabilities Net Minority Interest
397.26
Current Liabilities
138.85
Payables And Accrued Expenses
110.72
Payables
40.68
Accounts Payable
40.68
Current Accrued Expenses
70.04
Pensionand Other Post Retirement Benefit Plans Current
20.46
Total Tax Payable
0.00
Current Debt And Capital Lease Obligation
1.27
Current Debt
—
Other Current Borrowings
—
Current Capital Lease Obligation
1.27
Other Current Liabilities
6.41
Total Non Current Liabilities Net Minority Interest
258.40
Long Term Debt And Capital Lease Obligation
185.10
Long Term Debt
178.07
Long Term Capital Lease Obligation
7.04
Other Non Current Liabilities
73.30
Stockholders Equity
190.98
Common Stock Equity
190.98
Capital Stock
0.01
Common Stock
0.01
Preferred Stock
0.00
Share Issued
47.35
Ordinary Shares Number
47.35
Treasury Shares Number
0.00
Additional Paid In Capital
1,026.54
Retained Earnings
-835.57
Total Equity Gross Minority Interest
190.98
Total Capitalization
369.05
Working Capital
365.41
Invested Capital
369.05
Total Debt
186.37
Capital Lease Obligations
8.30
Net Tangible Assets
125.65
Tangible Book Value
125.65
Interest Payable
1.66
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-93.41
+27.26%
-128.41
+11.49%
-145.08
-24.52%
-116.51
Cash Flow From Continuing Operating Activities
-93.41
+27.26%
-128.41
+11.49%
-145.08
-24.52%
-116.51
Net Income From Continuing Operations
-183.17
+36.22%
-287.22
-20.05%
-239.24
-27.84%
-187.13
Depreciation Amortization Depletion
9.06
+13.90%
7.96
+16.45%
6.83
+55.25%
4.40
Depreciation
2.69
+71.71%
1.57
+241.18%
0.46
+74.52%
0.26
Amortization Cash Flow
6.38
-0.27%
6.39
+0.27%
6.38
+54.02%
4.14
Depreciation And Amortization
9.06
+13.90%
7.96
+16.45%
6.83
+55.25%
4.40
Amortization Of Intangibles
6.38
-0.27%
6.39
+0.27%
6.38
+54.02%
4.14
Other Non Cash Items
-0.91
-102.86%
31.73
-40.24%
53.10
+1000.44%
4.83
Stock Based Compensation
93.75
+10.01%
85.22
+36.09%
62.62
+65.99%
37.73
Operating Gains Losses
10.38
—
—
—
Change In Working Capital
-22.52
-166.44%
33.90
+219.40%
-28.39
-219.95%
23.67
Change In Receivables
-82.46
-74.78%
-47.18
+17.40%
-57.12
-51.52%
-37.70
Changes In Account Receivables
-82.46
-74.78%
-47.18
+17.40%
-57.12
-51.52%
-37.70
Change In Inventory
-15.67
-542.48%
-2.44
+45.34%
-4.46
+15.41%
-5.28
Change In Prepaid Assets
-1.67
+56.69%
-3.86
+27.59%
-5.33
-95.06%
-2.73
Change In Payables And Accrued Expense
77.28
-11.56%
87.38
+126.82%
38.53
-44.47%
69.38
Change In Accrued Expense
83.74
+49.37%
56.06
+53.81%
36.45
-17.01%
43.92
Change In Payable
-6.46
-120.63%
31.32
+1410.03%
2.07
-91.85%
25.46
Change In Account Payable
-6.46
-120.63%
31.32
+1410.03%
2.07
-91.85%
25.46
Change In Other Current Assets
—
—
—
—
Investing Cash Flow
-0.48
-77.78%
-0.27
+53.61%
-0.58
+98.92%
-53.70
Cash Flow From Continuing Investing Activities
-0.48
-77.78%
-0.27
+53.61%
-0.58
+98.92%
-53.70
Net PPE Purchase And Sale
-0.48
-77.78%
-0.27
+53.61%
-0.58
+17.09%
-0.70
Purchase Of PPE
-0.48
-77.78%
-0.27
+53.61%
-0.58
+17.09%
-0.70
Capital Expenditure
-0.48
-77.78%
-0.27
+53.61%
-0.58
+17.09%
-0.70
Net Business Purchase And Sale
—
0.00
0.00
+100.00%
-53.00
Purchase Of Business
—
0.00
0.00
+100.00%
-53.00
Financing Cash Flow
101.47
+75.42%
57.84
-82.53%
331.01
+16.32%
284.58
Cash Flow From Continuing Financing Activities
101.47
+75.42%
57.84
-82.53%
331.01
+16.32%
284.58
Net Issuance Payments Of Debt
-4.11
-315.35%
-0.99
-101.16%
85.00
+88.89%
45.00
Issuance Of Debt
330.00
0.00
-100.00%
85.00
+88.89%
45.00
Repayment Of Debt
-334.11
-33648.69%
-0.99
0.00
0.00
Long Term Debt Issuance
330.00
0.00
-100.00%
85.00
+88.89%
45.00
Long Term Debt Payments
-334.11
-33648.69%
-0.99
0.00
0.00
Net Long Term Debt Issuance
-4.11
-315.35%
-0.99
-101.16%
85.00
+88.89%
45.00
Net Common Stock Issuance
67.90
+66.50%
40.78
-84.24%
258.75
+6.15%
243.76
Proceeds From Stock Option Exercised
59.56
+94.13%
30.68
+147.04%
12.42
+98.67%
6.25
Net Other Financing Charges
-21.89
-73.22%
-12.63
+49.78%
-25.16
-141.14%
-10.43
Changes In Cash
7.58
+110.70%
-70.84
-138.22%
185.35
+62.06%
114.37
Beginning Cash Position
315.35
-18.34%
386.19
+92.29%
200.84
+132.26%
86.47
End Cash Position
322.93
+2.40%
315.35
-18.34%
386.19
+92.29%
200.84
Free Cash Flow
-93.89
+27.04%
-128.68
+11.66%
-145.66
-24.27%
-117.21
Interest Paid Supplemental Data
14.63
-25.72%
19.69
+17.69%
16.73
+117.67%
7.69
Common Stock Issuance
67.90
+66.50%
40.78
-84.24%
258.75
+6.15%
243.76
Issuance Of Capital Stock
67.90
+66.50%
40.78
-84.24%
258.75
+6.15%
243.76
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category